Current Bisphosphonates News and Events | Page 6

Current Bisphosphonates News and Events, Bisphosphonates News Articles.
Sort By: Most Relevant | Most Viewed
Page 6 of 6 | 208 Results
Remedies to bone loss in space may benefit Earth patients first
Spinal cord injury patients may be the first to benefit from studies to reduce bone loss in astronauts on long missions. The drug zoledronate is being studied to see if it can inhibit bone loss in spinal cord injury patients. (2001-11-28)

Study shows Actonel® reduces vertebral fracture risk 70 percent in patients on chronic steroid therapy
Bisphosphonates Recommended by American College of Rheumatology (ACR) for Glucocorticoid-Induced Osteoporosis (GIO). Vertebral fracture risk in men and women who take oral glucocorticoid treatment (> 7.5 mg/day prednisone or equivalent) for chronic diseases is significantly reduced with Actonel® (risedronate sodium tablets) 5 mg in just one year, according to data presented today at the 66th Annual Scientific Meeting of the American College of Gastroenterology in Las Vegas. (2001-10-24)

New treatment guidelines recommend bisphosphonates as first-line therapy for prevention and treatment of glucocorticoid-induced osteoporosis
New treatment guidelines published in the current issue of Arthritis and Rheumatism by the American College of Rheumatology (ACR) recommend bisphosphonates as first-line therapy in conjunction with calcium and vitamin D for preventing and treating glucocorticoid-induced osteoporosis (GIO), or steroid-induced bone loss. (2001-07-19)

OSU scientists link rapid bone loss to chemotherapy
Scientists at The Ohio State University Comprehensive Cancer Center say chemotherapy in young, early-stage breast cancer patients often leads to rapid and significant bone loss within months of beginning treatment. Some patients experienced bone loss at four-fold the amount a normal post-menopausal woman would encounter. Interim findings were so startling that a part of the study was halted to allow participants to seek intervention with their primary care physicians. (2001-07-11)

Very low doses of a potent new drug reduces the complications of bone metastases in patients with metastatic breast cancer and multiple myeloma
Researchers at Cedars-Sinai Medical Center report that very low doses of a potent new drug called zoledronic acid reduces the complications that arise from multiple myeloma and breast cancer that has spread to the bone. The study, published in the April 1st issue of the journal, Cancer, shows that a five-minute infusion of zoledronic acid works as effectively as much higher doses of a similar therapy called pamidronate, which is given over a two-hour time period. (2001-03-31)

Osteoporosis: catching a time bomb among the elderly
In this study, Dr. Ernest Hajcsar and colleagues surveyed patients who had presented to Ontario fracture clinics with fractures associated with bone fragility. The authors sought to determine whether the patients had been treated for osteoporosis. (2000-10-02)

Ohio researcher receives national award
M. David Francis of Wyoming, Ohio, will be honored on August 20 by the world's largest scientific society for his pioneering role in developing fluoride additives for toothpaste, bone-strengthening pharmaceuticals and other medical products. He will be designated one of 12 Heroes of Chemistry by the American Chemical Society at its 220th national meeting, in Washington, D.C. (2000-08-17)

Novartis submits NDA for Zometa® (zoledronic acid for injection)
Novartis Pharmaceuticals Corporation today announced that it has submitted a new drug application (NDA) to the U.S. Food and Drug Administration for Zometa (zoledronic acid for injection) for the treatment of tumor-induced hypercalcemia (TIH). A potentially life-threatening disorder, TIH is characterized by elevated serum calcium levels in patients with cancer. Tumor-induced hypercalcemia is one of the most common metabolic complications associated with cancer. (1999-12-21)

Page 6 of 6 | 208 Results
   First   Previous   Next      Last   
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.